Compare AEVA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | TBPH |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | 276 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.5M | 824.9M |
| IPO Year | N/A | 2013 |
| Metric | AEVA | TBPH |
|---|---|---|
| Price | $12.69 | $16.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $26.50 | $17.80 |
| AVG Volume (30 Days) | ★ 1.3M | 567.2K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $85.37 | $9.51 |
| Revenue Next Year | $132.72 | N/A |
| P/E Ratio | ★ N/A | $7.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.81 | $8.09 |
| 52 Week High | $38.79 | $21.03 |
| Indicator | AEVA | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 55.15 |
| Support Level | $12.44 | $13.41 |
| Resistance Level | $17.51 | $19.04 |
| Average True Range (ATR) | 1.33 | 0.52 |
| MACD | -0.26 | 0.37 |
| Stochastic Oscillator | 24.00 | 87.42 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.